COMP <GO>
GKOS vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Glaukos Corporation (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: GKOS 4
— MRK 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $237.60 (-2.01%) • MKT CAP: $14.35B
options-implied-move
7.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GKOS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GKOS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.70% | 74.80% | -19.10 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.70% | 20.70% | -34.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 3.42% | -3.58 | MRK | /fcf-yield <GO> |
| Operating Margin | -39.30% | 34.30% | -73.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -37.00% | 28.10% | -65.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 32.30% | 1.30% | +31.00 | GKOS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | GKOS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 82.6 | 56.9 | +25.72 | GKOS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.92 | +0.12 | GKOS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 18.4x | +15.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.35B | $361.02B | -$346.67B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GKOS REV | MRK REV | GKOS GROSS % | MRK GROSS % | GKOS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $507.4M | $65.01B | 55.7% | 74.8% | -$22.5M | $12.36B |
| FY 2024 | $383.5M | $64.17B | 75.5% | 76.3% | -$67.6M | $18.10B |
| FY 2023 | $314.7M | $60.12B | 44.0% | 44.0% | -$71.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GKOS // BETA 1.04
MRK // BETA 0.92